
By Jensey

Antibodies Formation in Mammals, and Uses Thereof in Gene Therapy, Animal Transgenesis an in Functional Inactivation of an Endogenous Protein(s)

Inventor(s): Amine Abina Appl. No.: 09/920,902



ID adhu TPO: •


TD adhu TPO: 0

control virus:

FIG.1


Inventor(s): Amine Abina Appl. No.: 09/920,902





platelet number x 104/µl

Inventor(s): Amine Abina Appl. No. 09/920,902




TPO/neutralized/ml of serum

Anti-TPO neutralizing activity in mice sera

Inventor(s): Amme Abina Appl. No.: 09/920,902

→ ID-M1(W5) → ID-M2(W13) → TD-M1(W5) → TD-M2(W5)




lgG2a anti-huTPO

FIG.4A

Inventor(s): Amine Abina Appl. No.: 09/920,902

→ ID-M1(W5) → ID-M2(W13) → TD-M1(W5) → TD-M2(W5)



lgG2a anti-huTPO

FIG.4B

Inventor(s): Amine Abina Appl. No.: 09/920,902

Cross-reactivity of B-cell hybridomas (1gG 2a)





FIG.5A

Inventor(s). Amine Abina Appl. No., 09/920,902

→ 1B(muTPO) → 1B(huTP0) Cross-reactivity of B-cell hybridomas (1gG 2b) FIG.5B dilutions 1/10 0.5 0

mn 294 (10

Inventor(s): Amine Abina Appl. No.: 09/920,902



Inventor(s): Amine Abina Appl. No : 09:920,902

→ IDM1(W13) → TDM1(W9) → TDM2(W9) --- IDM2(W4) lgG1 anti-adenovirus dilutions 0.5 0 5.

mn 294 (10

Inventor(s): Amine Abina Appl. No.: 09/920,902

